Semaglutide for Smoking Cessation in Patients With Diabetes
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorOttawa Heart Institute Research Corporation
About this trial
To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.
Eligibility criteria
Qualifiers
Adults (18 years or older) with type 2 diabetes
Currently residing in Ontario
Smoke at least five cigarettes per day and willing to reduce or quit smoking within the next 6 months
Stable HbA1c ≥7.0% - 10% with no more than a 1% change over the last 3 to 6 months.
Disqualifiers
Pregnant or breastfeeding individuals
Contraindication to NRT or GLP-1 RA.
Current daily use of NRT or a GLP1 RA.
Use of bupropion, cytisine, and varenicline within the last 7 days.
Trial design
Treatments tested in this trial
- Semaglutide
- Nicotine replacement
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov